diff --recursive ./downloaded_studies/exp_aml_ohsu_2022_sorted/README.txt ./re-downloaded_studies/exp_aml_ohsu_2022_sorted/README.txt
2c2
< This is a README file for the study aml_ohsu_2022.
---
> This is a README file for the study exp_aml_ohsu_2022.
diff --recursive ./downloaded_studies/exp_aml_ohsu_2022_sorted/data_clinical_sample_attributes.txt ./re-downloaded_studies/exp_aml_ohsu_2022_sorted/data_clinical_sample_attributes.txt
16c16
< aml_ohsu_2022_2010	aml_ohsu_2022_2010_BA2304	52	52	0		Acute Myeloid Leukemia	Therapy-related myeloid neoplasms		3	Waves1+2	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Intermediate	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[5]	-1	FALSE	Negative	AML	11q23 (MLL): rearrangement present (89.5%)	Complete Response		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow 	0	0.066666667		Yes	KRAS (p.Gly13Asp; MAF 38.9%)
---
> aml_ohsu_2022_2010	aml_ohsu_2022_2010_BA2304	52	52	0		Acute Myeloid Leukemia	Therapy-related myeloid neoplasms		3	Waves1+2	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Intermediate	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[5]	-1	FALSE	Negative	AML	11q23 (MLL): rearrangement present (89.5%)	Complete Response		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow	0	0.066666667		Yes	KRAS (p.Gly13Asp; MAF 38.9%)
111c111
< aml_ohsu_2022_2091	aml_ohsu_2022_2091_BA2684	2	5	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		1	Waves1+2	5	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Residual	NonInitial	M5	Negative	FALSE	FALSE	FALSE	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	-1	FALSE	Negative	AML		Complete Response		UNMATCHED	FALSE	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood		0	0.033333333		Yes	
---
> aml_ohsu_2022_2091	aml_ohsu_2022_2091_BA2684	2	5	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		1	Waves1+2	5	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Residual	NonInitial	M5	Negative	FALSE	FALSE	FALSE	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	-1	FALSE	Negative	AML		Complete Response		UNMATCHED	FALSE	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood		0	0.033333333		Yes	
148c148
< aml_ohsu_2022_2128	aml_ohsu_2022_2128_BA2148	31	31	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		2	Waves1+2	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	95	FALSE	Negative	AML	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20	Complete Response i		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), 	0	0.066666667		Yes	
---
> aml_ohsu_2022_2128	aml_ohsu_2022_2128_BA2148	31	31	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		2	Waves1+2	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	95	FALSE	Negative	AML	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20	Complete Response i		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-),	0	0.066666667		Yes	
289c289
< aml_ohsu_2022_2242	aml_ohsu_2022_2242_BA2836	59	59	0		Acute Myeloid Leukemia	AML with mutated NPM1		2	Waves1+2	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XY[20]	107	FALSE	Positive	AML	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Complete Response		MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), 	0	0.733333333		Yes	CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)
---
> aml_ohsu_2022_2242	aml_ohsu_2022_2242_BA2836	59	59	0		Acute Myeloid Leukemia	AML with mutated NPM1		2	Waves1+2	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XY[20]	107	FALSE	Positive	AML	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Complete Response		MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+),	0	0.733333333		Yes	CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)
333c333
< aml_ohsu_2022_2281	aml_ohsu_2022_2281_BA2995	71	71	0		Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS		2	Waves1+2	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Adverse		Negative	FALSE	FALSE	FALSE	46,XY	55	FALSE	Negative	AML	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]		RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%)	MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial 	0	1.1		Yes	
---
> aml_ohsu_2022_2281	aml_ohsu_2022_2281_BA2995	71	71	0		Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS		2	Waves1+2	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Adverse		Negative	FALSE	FALSE	FALSE	46,XY	55	FALSE	Negative	AML	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]		RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%)	MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial	0	1.1		Yes	
350c350
< aml_ohsu_2022_2294	aml_ohsu_2022_2294_BA2276	80	80	0		Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS		2	Waves1+2	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care	Decitabine, ABT-199	Unknown	Initial Diagnosis	Intermediate		Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	FALSE	Negative	AML	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim 	0	1.1		Yes	
---
> aml_ohsu_2022_2294	aml_ohsu_2022_2294_BA2276	80	80	0		Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS		2	Waves1+2	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care	Decitabine, ABT-199	Unknown	Initial Diagnosis	Intermediate		Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	FALSE	Negative	AML	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim	0	1.1		Yes	
590c590
< aml_ohsu_2022_2502	aml_ohsu_2022_2502_BA2666	77	77	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		2	Waves1+2	1	Vincristine, Dexamethasone	1	Supportive/Palliative Care	Vincristine, Dexamethasone	Supportive/Palliative Care	Initial Diagnosis	Adverse		Negative	TRUE	FALSE	FALSE	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	13	FALSE	Negative	AML	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), 	0	0.866666667	TP53 (p.R280Efs*65; 35.7%)|TP53 (p.R175H; 27.2%)	Yes	
---
> aml_ohsu_2022_2502	aml_ohsu_2022_2502_BA2666	77	77	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		2	Waves1+2	1	Vincristine, Dexamethasone	1	Supportive/Palliative Care	Vincristine, Dexamethasone	Supportive/Palliative Care	Initial Diagnosis	Adverse		Negative	TRUE	FALSE	FALSE	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	13	FALSE	Negative	AML	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +),	0	0.866666667	TP53 (p.R280Efs*65; 35.7%)|TP53 (p.R175H; 27.2%)	Yes	
654c654
< aml_ohsu_2022_2559	aml_ohsu_2022_2559_BA2427	53	60	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		4	Waves1+2	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction|Re-induction	Azacitidine, Gemtuzumab	Re-induction	Relapse	NonInitial	M4eo	Negative	FALSE	TRUE	FALSE	47,XX,t(16;16)(p13;q22),+22[20]	-1	FALSE	Negative	AML	CBFB inv(16)	Refractory		UNMATCHED	FALSE	Post-Chemotherapy|Relapse	Peripheral Blood	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM), 	0	0.1		Yes	FLT3-D835
---
> aml_ohsu_2022_2559	aml_ohsu_2022_2559_BA2427	53	60	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		4	Waves1+2	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction|Re-induction	Azacitidine, Gemtuzumab	Re-induction	Relapse	NonInitial	M4eo	Negative	FALSE	TRUE	FALSE	47,XX,t(16;16)(p13;q22),+22[20]	-1	FALSE	Negative	AML	CBFB inv(16)	Refractory		UNMATCHED	FALSE	Post-Chemotherapy|Relapse	Peripheral Blood	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM),	0	0.1		Yes	FLT3-D835
675c675
< aml_ohsu_2022_2580	aml_ohsu_2022_2580_BA3042	32	38	0		Acute Myeloid Leukemia	AML with maturation		1	Waves1+2	9	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, 	6	Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Decitabine, Sirolimus	Salvage	Residual	NonInitial	M2	Negative	FALSE	FALSE	FALSE	46,XX[19]/46,XY[1]	127	FALSE	Negative	AML	Normal	Complete Response		UNMATCHED	FALSE	Residual Disease|Post-Transplant	Bone Marrow Aspirate		488	0.166666667		Yes	CEBPA (Q305?Q312del RNVETQ; MAF 50%)|CEBPA (Y108*(premature stop codon); MAF 50%)|IKZF1 (p.G151R; MAF 40%)|NOTCH1 (p.G2152S; MAF: 50%)
---
> aml_ohsu_2022_2580	aml_ohsu_2022_2580_BA3042	32	38	0		Acute Myeloid Leukemia	AML with maturation		1	Waves1+2	9	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan,	6	Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Decitabine, Sirolimus	Salvage	Residual	NonInitial	M2	Negative	FALSE	FALSE	FALSE	46,XX[19]/46,XY[1]	127	FALSE	Negative	AML	Normal	Complete Response		UNMATCHED	FALSE	Residual Disease|Post-Transplant	Bone Marrow Aspirate		488	0.166666667		Yes	CEBPA (Q305?Q312del RNVETQ; MAF 50%)|CEBPA (Y108*(premature stop codon); MAF 50%)|IKZF1 (p.G151R; MAF 40%)|NOTCH1 (p.G2152S; MAF: 50%)
786c786
< aml_ohsu_2022_2680	aml_ohsu_2022_2680_BA3373	67	67	0		Acute Myeloid Leukemia	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1		1	Waves3+4	0		0		NONE	NONE	Initial Diagnosis	Adverse	M1	Negative	FALSE	FALSE	TRUE	45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]		FALSE	Negative	AML	EGR-1/ D5S23, D5S721:  96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7:  98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent 			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD5, CD7,  partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58,  dim CD71, CD117, dim CD123, dim HLA-DR and MPO+	0	0.1		Yes	DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%)
---
> aml_ohsu_2022_2680	aml_ohsu_2022_2680_BA3373	67	67	0		Acute Myeloid Leukemia	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1		1	Waves3+4	0		0		NONE	NONE	Initial Diagnosis	Adverse	M1	Negative	FALSE	FALSE	TRUE	45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]		FALSE	Negative	AML	EGR-1/ D5S23, D5S721:  96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7:  98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent			MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD5, CD7,  partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58,  dim CD71, CD117, dim CD123, dim HLA-DR and MPO+	0	0.1		Yes	DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%)
790c790
< aml_ohsu_2022_2684	aml_ohsu_2022_2684_BA3296	18	18	0		Acute Myeloid Leukemia	Myeloid sarcoma		1	Waves3+4	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation	2	Re-induction|Allogeneic - Matched Unrelated Donor	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Intermediate		Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	FALSE	Negative	AML	MLL (11q23):   88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid T			UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)	0	0		Yes	EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid 
---
> aml_ohsu_2022_2684	aml_ohsu_2022_2684_BA3296	18	18	0		Acute Myeloid Leukemia	Myeloid sarcoma		1	Waves3+4	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation	2	Re-induction|Allogeneic - Matched Unrelated Donor	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Intermediate		Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	FALSE	Negative	AML	MLL (11q23):   88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid T			UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)	0	0		Yes	EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid
847c847
< aml_ohsu_2022_2740	aml_ohsu_2022_2740_BA3162	20	20	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		2	Waves3+4	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	FALSE	Positive	AML	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	Complete Response		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), 	0	0.133333333		Yes	KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)
---
> aml_ohsu_2022_2740	aml_ohsu_2022_2740_BA3162	20	20	0		Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11		2	Waves3+4	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	HiDAC	Consolidation	Initial Diagnosis	Favorable		Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	FALSE	Positive	AML	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	Complete Response		UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-),	0	0.133333333		Yes	KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)
859c859
< aml_ohsu_2022_2752	aml_ohsu_2022_2752_BA3448	27	27	0		Acute Myeloid Leukemia	AML with minimal differentiation		1	Waves3+4	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	Initial Diagnosis	Adverse	M0	Negative	TRUE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[25]	-1	FALSE	Negative	AML	MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 	Complete Response		MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive	0	0.266666667		Yes	KRAS (p.G12D; MAF 16%)|MLL (PTD)
---
> aml_ohsu_2022_2752	aml_ohsu_2022_2752_BA3448	27	27	0		Acute Myeloid Leukemia	AML with minimal differentiation		1	Waves3+4	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	Initial Diagnosis	Adverse	M0	Negative	TRUE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[25]	-1	FALSE	Negative	AML	MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11	Complete Response		MATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive	0	0.266666667		Yes	KRAS (p.G12D; MAF 16%)|MLL (PTD)
935c935
< aml_ohsu_2022_2825	aml_ohsu_2022_2825_BA3415	79	79	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		1	Waves3+4	0		0		NONE	NONE	Initial Diagnosis	Adverse	M2	Negative	TRUE	FALSE	FALSE	49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]		FALSE	Negative	AML	EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype. 			UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO	0	0.066666667	TP53 (p.R196*; 89.6%)	Yes	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)
---
> aml_ohsu_2022_2825	aml_ohsu_2022_2825_BA3415	79	79	0		Acute Myeloid Leukemia	AML with myelodysplasia-related changes		1	Waves3+4	0		0		NONE	NONE	Initial Diagnosis	Adverse	M2	Negative	TRUE	FALSE	FALSE	49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]		FALSE	Negative	AML	EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.			UNMATCHED	FALSE	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO	0	0.066666667	TP53 (p.R196*; 89.6%)	Yes	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)
